CELGENE CORP. overview

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors PR Newswire SAN RAFAEL, Calif., Dec. 15, 2021 SAN RAFAEL, Calif. , Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles , to its Board of Directors effective January 1 , 2022. "We are thrilled to have Mark join BioMarin's Board of Directors. He...

Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”) issued a notice of redemption to The Bank of New York Mellon (successor to The Chase Manhattan Bank (National Association)), as trustee, to redeem (i) all of Bristol Myers Squibb’s 4.000% Notes due 2023 (CUSIP/ISIN Nos. 110122DA3/110122BL1/U11009AL8), originally issued on November 22, 2019, that remain outstanding after the early settlement of the previously announced tender offers (the “BMS 4.000% Notes”) and (ii)...

Thinking about trading options or stock in Apple, Celgene, Lowe's, NVIDIA, or Target? PR Newswire NEW YORK, Nov. 21, 2019 NEW YORK , Nov. 21, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CELG, LOW, NVDA, and TGT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing PR Newswire WALTHAM, Mass., Nov. 12, 2019 Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties....

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing PR Newswire WALTHAM, Massachusetts, Nov. 12, 2019 Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and...

Celgene Corporation (NASDAQ: CELG) reported third quarter 2019 total revenue of $4,520 million, a 16 percent increase compared to $3,892 million in the third quarter of 2018. Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene reported net income of $1,691 million and diluted earnings per share (EPS) of $2.32 for the third quarter of 2019. For the third quarter of 2018, GAAP net income was $1,082 million and diluted EPS was $1.50. Adjusted net income for the third quarter of...

Ovizio Imaging Systems Announces iLine F and BioConnect Supply Agreements With Celgene Corporation PR Newswire BRUSSELS, Oct. 22, 2019 BRUSSELS , Oct. 22, 2019 /PRNewswire/ -- Ovizio Imaging Systems, a company providing an innovative microscopic imaging technology to the bioprocessing market, today announces the execution of supply agreements with Celgene Corporation for the automation of certain engineered T cell manufacturing processes. Celgene will be using Ovizio's innovative on-line iLine F...

Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bristol-Myers Squibb Notes”) and cash and the related consent solicitations (the “Consent Solicitations”)...